欢迎来到CSNpharm！产品仅用于科研！

400-920-2911 sales@csnpharm.cn

NEW 新产品
0

DPP4

DPP4

货号 产品名 CAS号 信息
CSN19749 Zy15557 1601480-12-9 ZY15557 is a potent, competitive and long acting DPP-4 inhibitor showing similar DPP-4 inhibition across different species.
CSN12287 Vildagliptin 274901-16-5 Vildagliptin is an inhibitor of DPP-4 with IC50 of 2.3 nM that is used in the treatment of type 2 diabetes mellitus.
CSN21260 Vildagliptin dihydrate 2133364-01-7 Vildagliptin (LAF237 dihydrate;NVP-LAF 237 dihydrate) is a dipeptidyl peptidase 4 (DPP4) inhibitor that delays the degradation of glucagon-like peptide-1 (GLP-1).
CSN16203 Trelagliptin succinate 1029877-94-8 Trelagliptin succinate is an highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) that is used for the treatment of type 2 diabetes.
CSN16209 Trelagliptin 865759-25-7 Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).
CSN13813 Teneligliptin 760937-92-6 Teneligliptin is a potent and long-lasting dipeptidyl peptidase-4 inhibitor, and competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.
CSN17332 Bis(((2S,4S)-4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone) pentahydrobromide 906093-29-6 Teneligliptin Hydrobromide is a DPP4 inhibitor with IC50 value of <1 nM. It is commonly used as an add on treatment when meformin is not achieving the expected glycemic goals.
CSN13509 Talabostat mesylate 150080-09-4 Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases with IC50 of 1 nM for DPP4, including tumor-associated fibroblast activation protein.
CSN21888 Talabostat 149682-77-9 Talabostat (Val-boroPro) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor with IC50 < 4 nM and the first clinical inhibitor of fibroblast activation protein (FAP) with IC50 of 560 nM) and also inhibits DPP8/9 (IC50 = 4/11 nM).
CSN10172 Sitagliptin phosphate monohydrate 654671-77-9 Sitagliptin Phosphate Monohydrate is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.
CSN12755 Sitagliptin phosphate 654671-78-0 Sitagliptin phosphate is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.
CSN17002 (R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one 486460-32-6 Sitagliptin is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.
CSN13800 Saxagliptin hydrate 945667-22-1 Saxagliptin, the monohydrate form of anhydrous saxagliptin, is a reversible and selective DPP4 inhibitor with IC50 of 26 nM. It is used for the treatment of type 2 diabetes.
CSN24704 (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrochloride 709031-78-7 Saxagliptin, also known as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Saxagliptin was approved in 2008 for the treatment of type 2 diabetes. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus. .
CSN12346 (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile 361442-04-8 Saxagliptin is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
CSN21399 Saikogenin A 5092-09-1 Saikogenin A, extracted from a Chinese herbal plant called Tsai-Fu, is a dipeptidyl peptidase-IV (DPP-IV) inhibitor.
CSN20590 Retagliptin phosphate 1256756-88-3 Retagliptin phosphate is a DPP-4 inhibitor potentially used for the treatment of Type 2 diabetes.
CSN20588 Retagliptin 1174122-54-3 Retagliptin is a DPP-4 inhibitor potentially used for the treatment of Type 2 diabetes.
CSN20589 Retagliptin Hydrochloride 1174038-86-8 Retagliptin HCl is a DPP-4 inhibitor potentially used for the treatment of Type 2 diabetes.
CSN25708 PK44 phosphate 1017682-66-4 PK 44 phosphate is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV) with IC50 of 15.8 nM.
CSN13845 (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine 1226781-44-7 Omarigliptin, also called MA-3102, is an selective inhibitor of DPP-4 with IC50 of 1.6 nM and Ki of 0.8 nM. Its selectivity is higher than other 168 proteasomes.
CSN25709 NVP-DPP728 2HCl 207556-62-5 NVP DPP 728 dihydrochloride is active dipeptidyl peptidase (DPP)-IV inhibitor with Ki and IC50 of 11 nM, 14 nM respectively.
CSN22003 Gosogliptin 869490-23-3 Metabolic Disease
CSN12323 (R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione 668270-12-0 Linagliptin, a purine and quinazoline derivative, can inhibit DPP-4 with IC50 of 1 nM. It functions as an incretin and is used as a hypoglycemic agents in the treatment of type 2 diabetes mellitus.
CSN25705 K579 440100-64-1 K 579 is an inhibitor of dipeptidyl peptidase IV with IC50 value of 8 nM.
CSN20386 HBK001 1942922-78-2 HBK001 is a dual DPP4 inhibitor and GPR119 agonist that regulates glycemic control and beta cell function ex and in vivo.
CSN20422 Gemigliptin 911637-19-9 Gemigliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
CSN20545 Evogliptin tartrate 1222102-51-3 Evogliptin tartrate is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) which improves insulin resistance and delays the onset of diabetes.
CSN20543 Evogliptin 1222102-29-5 Evogliptin is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) which improves insulin resistance and delays the onset of diabetes.
CSN26633 Dutogliptin tartrate 890402-81-0 Dutogliptin, also known as PHX1149, is a selective and orally active DPP4 inhibitor. Dutogliptin improves glycaemic control in patients with type 2 diabetes. PP-4 inhibitors or gliptins, are a class of oral hypoglycemics that block DPP-4. They can be used to treat diabetes mellitus type 2. The first agent of the class - sitagliptin - was approved by the FDA in 2006.
CSN25706 rel-(2R,5S)-1-(2-((1-(Hydroxymethyl)cyclopentyl)amino)acetyl)pyrrolidine-2,5-dicarbonitrile hydrochloride 866396-70-5 DPPI 1c hydrochloride is inhibitor of dipeptidyl peptidase IV (DPP-IV) with IC50 of 104 nM.
CSN25707 Diprotin A 90614-48-5 Diprotin A is the inhibitor of dipeptidyl peptidase IV. It can inhibit entry of HIV-1 or HIV-2 into T lymphoblastoid and monocytoid cell lines.
CSN17532 DBPR108 1186426-66-3 DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM showing no inhibition on DDP8 and DPP9.
CSN25468 (2S)-2-((tert-Butoxycarbonyl)amino)-2-(3-hydroxyadamantan-1-yl)acetic acid 361442-00-4 Boc-3-hydroxy-1-adamantyl-D-glycine is used in the preparation of a Saxagliptin intermediate.
CSN16158 Anagliptin 739366-20-2 Anagliptin is a potent and selective DPP-4 inhibitor(IC50= 3.8 nM) and > 10 fold less potent for DPP-8 and DPP-9.
CSN10251 (R)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile 850649-61-5 Alogliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor with IC50 of 6.9 nM that exhibits greater selective than DPP-2, DPP-8 and DPP-9.
CSN12318 (R)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile benzoate 850649-62-6 Alogliptin benzoate is the benzoate salt form of alogliptin which is a selective inhibitor of DPP-4 with IC50 of 6.9 nM that exhibits greater selective than DPP-2, DPP-8 and DPP-9.
CSN25467 (2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetic acid 709031-29-8 3-Hydroxy-1-adamantyl-D-glycine is a non-proteinogenic amino acid , which is a key intermediate required for the synthesis of Saxagliptin (S143500).
<< PREV 1 2 NEXT >>
dandb BBB norton fedex dhl ups 顺丰

csnpharm版权所有2023，产品仅用于科研！

联系
我们